WO2017205779A3 - Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression - Google Patents

Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression Download PDF

Info

Publication number
WO2017205779A3
WO2017205779A3 PCT/US2017/034743 US2017034743W WO2017205779A3 WO 2017205779 A3 WO2017205779 A3 WO 2017205779A3 US 2017034743 W US2017034743 W US 2017034743W WO 2017205779 A3 WO2017205779 A3 WO 2017205779A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
inflammasome activity
disorders related
treating disorders
Prior art date
Application number
PCT/US2017/034743
Other languages
French (fr)
Other versions
WO2017205779A2 (en
Inventor
Victor M. Elner
Matthew FIELD
Michelle J. KAHLENBERG
Susan G. Elner
Zong-Mei BIAN
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of WO2017205779A2 publication Critical patent/WO2017205779A2/en
Publication of WO2017205779A3 publication Critical patent/WO2017205779A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention is concerned with the use of agents that inhibit CD40L-induced inflammasome activity. Indeed, described herein are methods, compositions and pharmaceutical compositions useful in inhibiting CD40L-induced inflammasome activity without inhibiting CD40 biological activity, and in treating subjects suffering from disorders related to CD40L-induced inflammasome activity and IL-1α expression.
PCT/US2017/034743 2016-05-27 2017-05-26 Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression WO2017205779A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342690P 2016-05-27 2016-05-27
US62/342,690 2016-05-27

Publications (2)

Publication Number Publication Date
WO2017205779A2 WO2017205779A2 (en) 2017-11-30
WO2017205779A3 true WO2017205779A3 (en) 2018-01-04

Family

ID=60411941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/034743 WO2017205779A2 (en) 2016-05-27 2017-05-26 Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression

Country Status (1)

Country Link
WO (1) WO2017205779A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110564730B (en) * 2019-07-18 2021-08-03 杨婷 CD40L aptamer and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140147445A1 (en) * 2010-10-21 2014-05-29 Baker Idi Heart & Diabetes Institute Holdings Ltd. Selective Targeting of the CD40L/Mac-1 Interaction by Small Peptide Inhibitors and its Use for the Treatment of Inflammation and Atherogenesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140147445A1 (en) * 2010-10-21 2014-05-29 Baker Idi Heart & Diabetes Institute Holdings Ltd. Selective Targeting of the CD40L/Mac-1 Interaction by Small Peptide Inhibitors and its Use for the Treatment of Inflammation and Atherogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DABHI ET AL.: "Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study", INDIAN J EXP BIOL., vol. 46, no. 6, 2008, pages 476 - 481, XP055450829 *
STROWIG ET AL.: "Inflammasomes in health and disease", NATURE, vol. 481, no. 7381, 2012, pages 278 - 286, XP055450830 *

Also Published As

Publication number Publication date
WO2017205779A2 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
EA201990665A1 (en) HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATION FOR TREATMENT OF CANCER
PH12017501611A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015077503A8 (en) Autotaxin inhibitor compounds
EA201391786A1 (en) HALOGEN-ALKYL-1,3-OXAZINS AS BACE1 AND / OR BACE2 INHIBITORS
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
EA201990424A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
WO2016109217A3 (en) Btk inhibitors
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EA201990428A1 (en) SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
PH12015502365B1 (en) Bace1 inhibitors
CN107406464A8 (en) Arginase inhibitor and its therapeutical uses
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201492097A1 (en) 5-AMINO [1,4] TIAZINS AS BETA SECRETASE INHIBITORS 1
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2019003458A (en) Non-solvated crystal, preparation method and application thereof.
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2020068950A8 (en) Hdac1,2 inhibitors
MX2018014185A (en) Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors.
PH12017501668A1 (en) Bace1 inhibitors
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17803690

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17803690

Country of ref document: EP

Kind code of ref document: A2